Related references
Note: Only part of the references are listed.Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer A Phase 3 Randomized Clinical Trial
Hope S. Rugo et al.
JAMA ONCOLOGY (2021)
Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Phase III NALA Trial
Cristina Saura et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Evaluating the evidence behind the surrogate measures included in the FDA's table of surrogate endpoints as supporting approval of cancer drugs
Bishal Gyawali et al.
ECLINICALMEDICINE (2020)
Association between progression-free survival and patients' quality of life in cancer clinical trials
Thomas J. Hwang et al.
INTERNATIONAL JOURNAL OF CANCER (2019)
Is the number of cancer drug approvals a surrogate for regulatory success?
Bishal Gyawali et al.
JOURNAL OF CANCER POLICY (2019)
Surrogate threshold effect: An alternative measure for meta-analytic surrogate endpoint validation
Tomasz Burzykowski et al.
PHARMACEUTICAL STATISTICS (2006)
Share Paper
